EP241/#516  PATIENT DERIVED ORGANOIDS AS EX-VIVO MODELS FOR HIGH GRADE SEROUS OVARIAN CANCER RESEARCH

James Clark, Christina Fotopoulos*, Jennifer Polski, Caitiona Dickie, Lydia Kondylidou, Jonathan Krell, Paula Cunnea. Imperial College London, Surgery and Cancer, London, UK

Introduction Patient-Derived Organoids (PDOs) are in increasing use as ex-vivo models for high-grade serous ovarian cancer (HGSOC) and other cancers, given their genotypic and phenotypic similarities with in vivo tumour. We aimed to characterise inter- and intrapatient heterogeneity in PDOs from multiple sites in chemo-naive HGSOC.

Methods Multi-site tumour samples were collected from HGSOC patients undergoing primary cytoreductive surgery and PDOs grown from extracted tumour cells with/without the Wnt agonist R-spondin. PDOs were trialled against chemotherapy and targeted therapeutics using IC50 and AUC for comparison. Transcriptomic differences between PDOs were explored using RNAseq.

Results PDOs were successfully established (≥5 passages) in 8/14 cases (57%), with a mean n=5 sites initially seeded per patient. IC50 and AUC values for platinum compounds and PARP inhibitors varied significantly between patients, and between different sites from the same patient. Cisplatin sensitivity varied 20-fold across 8 different PDO lines (p<0.0001), with carboplatin sensitivity differing by almost 10-fold between different tumour sites in one case (p<0.0001) highlighting HGSOC inter/intrapatient heterogeneity. Rucaparib sensitivity variability was demonstrated between cases and between sites from the same case (p<0.001). Resistance was induced in 2 PDO lines through cultivating in low dose conditions, with AUC increments were observed for cisplatin (p<0.01) and rucaparib (p<0.05) compared to controls. Potentially synergistic compounds to overcome platinum and PARPi resistance were trialled.

Conclusion/Implications HGSOC PDOs provide a reliable model for drug screening, incorporating inter and intra-patient heterogeneity. The heterogeneity observed provides rationale for variability in clinical responses and the poor prognosis consistent with advanced HGSOC.


1Stephen McCormack, 2Christina Fotopoulos*, 3Rowan Miller, 4Rebecca Bowen, 5Agnieszka Michael, 6Anthony Wesselbaum, 7Allan Ullmann, 8Ranjit Manchanda. 9GSK, Medical, London, UK; 10Imperial College London, Surgery and Cancer, London, UK; 11University College Hospital, Gynaecology and Early Phase Clinical Trials, London, UK; 12Royal United Hospitals Bath NHS Foundation Trust, Breast and Gynaecological Cancer, Bath, UK; 13Royal Surrey NHS Foundation Trust, Oncology Ovarian Cancer and Renal Cancer, Guildford, UK; 14Barts Health NHS Trust, Gynaecological Oncology, London, UK

Introduction Background Advanced high-grade ovarian cancer (OC) treatment has recently evolved to include novel targeted agents such as PARP-inhibitors. Our survey explores current management of advanced OC in the UK.

Methods Methodology This interim descriptive analysis uses data collected between March-April 2023 from structured interviews with UK-based healthcare professionals (HCPs) involved in secondary care management of advanced OC (OC-NOW).

Results The analysis included 50 OC MDT members. Respondents were mainly based in England (84%; 42/50). Most HCPs (68%; 19/28) used the DESKTOP-III criteria to identify candidates for secondary cytoreduction, with up to 30% of patients considered as eligible in 85% (23/27) of centres. HRD (100%; 41/41) and BRCA1/2 (98%; 40/41) were routinely tested before planning maintenance treatment. Most respondents (90%; 36/40) reported that HRD test results had a turnaround time of 6 weeks. The median number (interquartile range [IQR]) of patients with a BRCA mutation (BRCAmut) was 20.0% (15.0–20.0%), while 25.0% (18.8–30.0%) were HRD (test positive) and BRCA wild type (HRD/BRCAtwt), 49.0% (35.0–60.0%) were HRp (test negative) and 10.0% (5.0–11.2%) were HRod (HR test failure/not determined/inconclusive). Platinum sensitivity was seen as predictive of PARPi maintenance therapy benefit, irrespective of HRD status.

Conclusion/Implications Conclusion These results provide an update on UK practice in advanced OC. HRD and BRCA1/2 are now routinely assessed with turnaround times on time for maintenance therapy decision making. For Platinum Sensitive OC, PARPi maintenance is typically considered irrespective of HRD status.

Int J Gynecol Cancer 2023;33(Suppl 4):A1–A278

A177